Important Point - In my view: Current outstandi
Post# of 405
(Total Views: 658)
Posted On: 02/10/2017 5:46:06 PM
Important Point - In my view:
Current outstanding share count sits at 123M plus what will be 25.6M of Novalere's plus probably 11m or so hitting soon from the recent s-1. That in and of itself does not seem too good but let's do some math and think about some things, shall we?
** We were trading for days at .08 when revs were at 1m and o/s was at 48M. Guidance for all of 2017 is $15m WITHOUT FlutiCare.
So, assuming guidance is met (will probably be exceeded) but let's assume 15M revs with 160M o/s by end of year
.08 x 15 divided by 3.3 = .36
Again - this is without FlutiCare folks. Even if you are extremely pessimistic and say that you think a 1-2 r/s is coming by year end, then PPS = .18 (after a built-in 50% selloff) WHICH IS STILL HIGHER than today's PPS.
Now the reasoning part...WHY would FlutiCare not be approved ? Plus if Dr. Damaj and Novalere combined own 51M shares of the say 160M o/s, then 32% of the shares are literally LOCKED DOWN. Sure I suppose they COULD sell some but I think they would be likely not to do it ALL at once, if at all while the company executes on its business plan.
Point being - When FlutiCare is approved - not only do we get a HUGE revenue boost but Novalere will get royalty payments that kick in and would be less likely to sell INNV shares until a likely buyout happens- years down the road.
Currently Damaj and the board own a hair over 20% of the outstanding shares and by registering Novalere's, we will now have 32% of approx 160M LOCKED. This doesn't even count the loyal longs still holding on from 60 cents that haven't sold a share, like me. HMMMMMM, I wonder if Novalere and Bassam are friendly ?
Current outstanding share count sits at 123M plus what will be 25.6M of Novalere's plus probably 11m or so hitting soon from the recent s-1. That in and of itself does not seem too good but let's do some math and think about some things, shall we?
** We were trading for days at .08 when revs were at 1m and o/s was at 48M. Guidance for all of 2017 is $15m WITHOUT FlutiCare.
So, assuming guidance is met (will probably be exceeded) but let's assume 15M revs with 160M o/s by end of year
.08 x 15 divided by 3.3 = .36
Again - this is without FlutiCare folks. Even if you are extremely pessimistic and say that you think a 1-2 r/s is coming by year end, then PPS = .18 (after a built-in 50% selloff) WHICH IS STILL HIGHER than today's PPS.
Now the reasoning part...WHY would FlutiCare not be approved ? Plus if Dr. Damaj and Novalere combined own 51M shares of the say 160M o/s, then 32% of the shares are literally LOCKED DOWN. Sure I suppose they COULD sell some but I think they would be likely not to do it ALL at once, if at all while the company executes on its business plan.
Point being - When FlutiCare is approved - not only do we get a HUGE revenue boost but Novalere will get royalty payments that kick in and would be less likely to sell INNV shares until a likely buyout happens- years down the road.
Currently Damaj and the board own a hair over 20% of the outstanding shares and by registering Novalere's, we will now have 32% of approx 160M LOCKED. This doesn't even count the loyal longs still holding on from 60 cents that haven't sold a share, like me. HMMMMMM, I wonder if Novalere and Bassam are friendly ?
(1)
(0)Innovus Pharmaceuticals Inc. (INNV) Stock Research Links
Scroll down for more posts ▼